Zentalis Pharmaceuticals (ZNTL) Deferred Taxes (2022 - 2023)
Zentalis Pharmaceuticals' quarterly Deferred Taxes came in at -$756000.0 in Q2 2023, down 1121.62% year-on-year from $74000.0 in Q2 2022, and down 679.38% quarter-over-quarter from -$97000.0 in Q1 2023.
Zentalis Pharmaceuticals has reported Deferred Taxes for 2 years, with the latest figure at -$756000.0 in Q2 2023.
- For the quarter ending Q2 2023, Deferred Taxes fell 1121.62% year-over-year to -$756000.0; the trailing twelve-month figure through Mar 2024 stood at -$756000.0 (up 4.55% YoY), and the FY2023 full-year result was -$853000.0, down 10.92% from the prior year.
- Deferred Taxes for Q2 2023 stood at -$756000.0, down from -$97000.0 in the prior quarter.
- The five-year high for Deferred Taxes was $74000.0 in Q2 2022, with the low at -$769000.0 in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -65.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 96.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 9.31 Mn |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -756,000.00 |
| Mar 31, 2023 | -97,000.00 |
| Dec 31, 2022 | -769,000.00 |
| Jun 30, 2022 | 74,000.00 |
| Mar 31, 2022 | -74,000.00 |